New pre-surgery radiation plus ASTX660 for rectal cancer
Treatments studied
Part of Cancer clinical trials.
This early-phase trial tests adding ASTX660 (a new drug) to pre-surgery radiation for locally advanced rectal cancer. It aims to improve control of the tumor before surgery, making it more likely that the surgeon can remove it with clear margins.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older, and you have locally advanced rectal cancer that is likely to be hard to remove with clear margins without chemoradiotherapy
- Your pelvic MRI shows the tumor or lymph node is within 2 mm of the mesorectal fascia and/or has N2 lymph node involvement
- No metastatic (spread) cancer is seen on CT scans of the chest and abdomen
- You can have MRI (no MRI-incompatible devices, and you can tolerate the scan)
- You completed 4 to 6 cycles of mFOLFIRINOX as required in the appropriate treatment plan, and your general status is ECOG 0–1
- Your blood tests, pregnancy status (if applicable), and organ health must meet the study cutoffs, and you must be able to follow all visits and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of radiation therapy followed by a combination of three drugs (fruquintinib, adebrelimab, and CAPOX chemotherapy) before surgery for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
This Phase 2 trial compares a pre-surgery (neoadjuvant) treatment plan versus the standard plan for people with stage II–III rectal cancer. The goal is to see which approach works better and is safe before surgery.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.